SNDX Company Profile and Key Details

Q: Who are the executives of SNDX?

Sharon KlahreVice President of Investor Relations & CommunicationsDr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific OfficerDr. Briggs W. Morrison M.D.Pres, Head of R&D and DirectorDr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardDr. Michael Downes Ph.D.Co-FounderDr. Briggs W. Morrison M.D., Ph.D.Pres, Head of R&D and DirectorMr. Michael A. Metzger M.B.A.Chief Executive Officer & DirectorDr. Anjali Ganguli Ph.D.Chief Bus. OfficerMr. Keith Alan Goldan CPAChief Financial Officer, Treasurer & Chief Accounting OfficerMr. Steve M. SabusChief Commercial OfficerMr. Luke J. AlbrechtSenior Vice President, Gen. Counsel & Sec.Dr. Catherine Madigan M.D.Chief Medical OfficerMr. Alexander NolteInterim Chief Financial Officer, Principal Accounting Officer & Treasurer

NASDAQ : SNDX

Syndax Pharmaceuticals

$21.41

0.7844+3.80%

Open: 3:24 PM

55.95

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Syndax Pharmaceuticals, Inc. (SNDX) stock surged +3.80%, trading at $21.41 on NASDAQ, up from the previous close of $20.63. The stock opened at $20.92, fluctuating between $20.70 and $21.43 in the recent session.

Stock Snapshot

20.63

Prev. Close

1.89B

Market Cap

20.7

Day Low

-6.51

P/E Ratio

-3.29

EPS (TTM)

-2.21

Cash Flow per Share

20.92

Open

88.2M

Number of Shares

21.43

Day High

94.89%

Free Float in %

7.64

Book Value

742.46K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 29, 2026	20.99	21.01	20.37	20.63	2.42M
Apr 28, 2026	21.21	21.62	20.93	21.11	1.08M
Apr 27, 2026	21.39	21.75	20.64	21.00	1.32M
Apr 23, 2026	22.15	22.51	20.97	21.00	2.49M
Apr 22, 2026	23.50	23.70	21.77	22.08	2.23M
Apr 21, 2026	23.80	23.81	23.16	23.33	1.19M
Apr 20, 2026	24.31	24.33	23.71	23.78	785.29K
Apr 17, 2026	24.30	24.58	23.50	24.23	1.62M
Apr 16, 2026	24.35	24.35	23.46	23.81	817.13K
Apr 14, 2026	24.27	24.80	24.12	24.43	871.85K
Apr 13, 2026	24.74	25.21	23.90	24.25	834.41K
Apr 10, 2026	24.74	24.78	24.21	24.44	893.67K
Apr 09, 2026	24.40	24.94	24.28	24.76	707.39K
Apr 08, 2026	24.94	25.38	24.20	24.56	1.69M
Apr 07, 2026	24.05	24.67	23.63	24.64	1.09M
Apr 06, 2026	25.08	25.53	24.21	24.29	1.69M
Apr 02, 2026	23.44	25.52	23.21	25.15	2.08M
Apr 01, 2026	23.91	24.53	23.14	23.88	2.27M
Mar 31, 2026	23.48	24.17	23.10	23.36	2.73M
Mar 30, 2026	23.57	23.57	22.40	22.48	1.49M

Contact Details

New York City, MA 02451

United States

https://www.syndax.com 781 419 1400

About Company

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Stock Peers

ARGX

0.99+0.13%

argenx SE$776.02 REGN

-45.41-6.21%

Regeneron Pharmaceuticals, Inc.$686.36 UTHR

1.96+0.34%

United Therapeutics Corporation$571.07 MDGL

1.89+0.37%

Madrigal Pharmaceuticals, Inc.$518.58 VRTX

-6.9-1.60%

Vertex Pharmaceuticals Incorporated$423.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

1.27+0.39%

Praxis Precision Medicines, Inc.$323.19 ALNY

-0.92-0.30%

Alnylam Pharmaceuticals, Inc.$301.19 KRYS

-9.32-3.46%

Krystal Biotech, Inc.$259.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Syndax Pharmaceuticals, Inc. (SNDX) stock price?

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) stock price is $21.41 in the last trading session. During the trading session, SNDX stock reached the peak price of $21.43 while $20.70 was the lowest point it dropped to. The percentage change in SNDX stock occurred in the recent session was 3.8% while the dollar amount for the price change in SNDX stock was $0.78.

SNDX's industry and sector of operation?

The NASDAQ listed SNDX is part of Biotechnology industry that operates in the broader Healthcare sector. Syndax Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SNDX?

Sharon Klahre
Vice President of Investor Relations & Communications
Dr. Peter Ordentlich B.Sc., Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Briggs W. Morrison M.D.
Pres, Head of R&D and Director
Dr. Ronald M. Evans Ph.D.
Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D.
Co-Founder
Dr. Briggs W. Morrison M.D., Ph.D.
Pres, Head of R&D and Director
Mr. Michael A. Metzger M.B.A.
Chief Executive Officer & Director
Dr. Anjali Ganguli Ph.D.
Chief Bus. Officer
Mr. Keith Alan Goldan CPA
Chief Financial Officer, Treasurer & Chief Accounting Officer
Mr. Steve M. Sabus
Chief Commercial Officer
Mr. Luke J. Albrecht
Senior Vice President, Gen. Counsel & Sec.
Dr. Catherine Madigan M.D.
Chief Medical Officer
Mr. Alexander Nolte
Interim Chief Financial Officer, Principal Accounting Officer & Treasurer

How SNDX did perform over past 52-week?

SNDX's closing price is 140.44% higher than its 52-week low of $8.58 where as its distance from 52-week high of $25.59 is -19.38%.

How many employees does SNDX have?

Number of SNDX employees currently stands at 270.

Link for SNDX official website?

Official Website of SNDX is: https://www.syndax.com

How do I contact SNDX?

SNDX could be contacted at phone 781 419 1400 and can also be accessed through its website. SNDX operates from 35 Gatehouse Drive, New York City, MA 02451, United States.

How many shares of SNDX are traded daily?

SNDX stock volume for the day was 742.46K shares. The average number of SNDX shares traded daily for last 3 months was 1.54M.

What is the market cap of SNDX currently?

The market value of SNDX currently stands at $1.89B with its latest stock price at $21.41 and 88.2M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	270
Beta	0.41
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	270
Beta	0.41
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SNDX Company Profile and Key Details

Syndax Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook